During or after treatment with EGFR TKIs, a subset of individuals (i.e., 5–10%) with NSCLC and EGFR mutations develops histologic transformation of adenocarcinoma into small-cell lung cancer (SCLC) [78, 80–82]. The gene discussed is EGFR; the disease is adenocarcinoma.